SCHEMBL531475

SCHEMBL531475

O=C(O)CC=CCc1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.65
TOP1 P11387 1/20 0.59
PAM P19021 1/20 0.55
ALDH1A1 P00352 1/20 0.52
CYP2D6 P10635 1/20 0.52
ALOX15 P16050 1/20 0.52
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
ARG2 P78540 1/20 0.50
AKR1B1 P15121 1/20 0.48
KEAP1 Q14145 1/20 0.45
CES2 O00748 1/20 0.43
CES1 P23141 1/20 0.43
CYP2C19 P33261 1/20 0.42
HDAC3 O15379 1/20 0.42
MAPK1 P28482 1/20 0.42
ADRA1A P35348 1/20 0.42
HDAC4 P56524 1/20 0.42
SLC6A3 Q01959 1/20 0.42
HDAC1 Q13547 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL531474 1.00 MAOB (0.65) MAOBTOP1PAMALDH1A1CYP2D6
SCHEMBL27988130 0.87 MAOB (0.65) MAOBTOP1PAMCA1CA2
SCHEMBL6969824 0.85 MAOB (0.62) MAOBTOP1PAMALDH1A1CA1
SCHEMBL27489761 0.83 MAOB (0.60) MAOBTOP1PAMALDH1A1CA1
SCHEMBL13784804 0.83 MAOB (0.60) MAOBTOP1PAMALDH1A1CA1
SCHEMBL16050000 0.81 AKR1B1 (0.71) MAOBTOP1ALDH1A1CA1CA2
SCHEMBL16050220 0.81 AKR1B1 (0.71) MAOBTOP1ALDH1A1CA1CA2
SCHEMBL155055 0.81 MAOB (1.00) MAOBTOP1ALDH1A1ALOX15CA1
SCHEMBL1524697 0.81 MAOB (1.00) MAOBTOP1ALDH1A1ALOX15CA1
SCHEMBL155054 0.81 MAOB (1.00) MAOBTOP1ALDH1A1ALOX15CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-7118199-A None JP disclosed
US-11896593-B2 Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder BIO-PHARM SOLUTIONS CO., LTD. (KR) 2024-02-13 US disclosed
EP-4211125-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER Bio-Pharm Solutions Co., Ltd. (KR) 2023-07-19 EP disclosed
CN-116234798-A Sulfamate derivative compounds for the treatment or alleviation of psychotic disorders 生物药品解决方案有限公司 2023-06-06 CN disclosed
US-20220218702-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER BIO-PHARM SOLUTIONS CO., LTD. (KR) 2022-07-14 US disclosed
WO-2022054987-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER BIO-PHARM SOLUTIONS CO., LTD. (KR) 2022-03-17 WO disclosed
CN-106507667-B Sulfamate derivatives for the prevention or treatment of epilepsy 比皮艾思药物研发有限公司 2020-01-24 CN disclosed
EP-3443959-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN Bio-Pharm Solutions Co., Ltd. (KR) 2019-02-20 EP disclosed
EP-3079685-B1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN BIO PHARM SOLUTIONS CO LTD (KR) 2018-11-28 EP disclosed
EP-3079686-B1 SULFAMATE DERIVATIVE COMPOUND FOR USE IN PREVENTING OR TREATING EPILEPSY BIO PHARM SOLUTIONS CO LTD (KR) 2018-10-24 EP disclosed
EP-0762837-A1 PROCESS FOR IMPROVING THE SHELF LIFE OF AND/OR STABILISING PRODUCTS WHICH CAN SPOIL UNDER THE ACTION OF MICROBES Schür, Jörg-Peter (DE) 1997-03-19 EP disclosed
WO-1996029895-A1 PROCESS FOR IMPROVING THE SHELF LIFE OF AND/OR STABILISING PRODUCTS WHICH CAN SPOIL UNDER THE ACTION OF MICROBES SCHUER JOERG PETER (DE) 1996-10-03 WO disclosed
JP-H07118199-A SEPARATION OF 5-PHENYLPENTANOIC ACID KURARAY CO LTD 1995-05-09 JP disclosed
CN-1079648-A Preparation contains the method for the pharmaceutical composition of imidazolyl-alkenoic acids SMITHKLINE BEECHAM CORP (US) 1993-12-22 CN disclosed
CN-1048039-A Imidazolyl-alkenoic acids SMITHKLINE BEECHAM CORP (US) 1990-12-26 CN disclosed
EP-0042026-B1 3,4-DISUBSTITUTED AZETIDIN-2-ON COMPOUNDS AND PROCESS FOR THEIR PREPARATION CIBA-GEIGY AG (CH) 1986-01-08 EP disclosed
EP-0003960-B1 6-SUBSTITUTED THIA-AZA-COMPOUNDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM CIBA-GEIGY AG (CH) 1983-06-29 EP disclosed
EP-0042026-A1 3,4-Disubstituted azetidin-2-on compounds and process for their preparation CIBA-GEIGY AG (CH) 1981-12-23 EP disclosed
EP-0035183-A2 Use of 2-phenyl-1(2)-propen-1-yl carboxylic acid esters as perfuming agents, their preparation and perfuming compositions containing them Henkel Kommanditgesellschaft auf Aktien (DE) 1981-09-09 EP disclosed
EP-0003960-A1 6-Substituted thia-aza-compounds, their preparation and pharmaceutical compositions containing them CIBA-GEIGY AG (CH) 1979-09-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220218702-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER SLC6A4, SLC6A3, SLC6A2 MAOB 245/4885TOP1 3546/4885PAM 3578/4885
US-11896593-B2 Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder SLC6A4, SLC6A3, SLC6A2 MAOB 245/4885TOP1 3546/4885PAM 3578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.